ArticleJCO precision oncology2026
Clinicogenomic Landscape of Histologic Subtypes in Ovarian Cancer: Real-World Evidence From a Japanese Nationwide Cohort.
Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Receptor Co‑targeting Strategies for Personalized Ovarian Cancer Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe frequency of histologic subtypes in epithelial ovarian cancer (EOC) varies by geographic region. In Western countries, high-grade serous ovarian cancer (HGSOC) is the most common and well characterized, whereas non-HGSOC subtypes, particularly clear cell ovarian cancer (CCOV), are more prevalent in Asia. However, their clinicogenomic features remain poorly defined. PATIENTS AND
methodsThis retrospective study analyzed real-world data from Japan's Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database. The cohort included 5,395 patients diagnosed with ovarian cancer between January 2016 and June 2025. Clinical characteristics, treatment patterns, and real-world overall survival (rwOS) were evaluated in histologic subtypes. Comprehensive genomic profiling was used to characterize mutational landscapes and to identify genomic biomarkers associated with rwOS.
resultsEOCs were classified into five histologic subtypes: HGSOC (51%), low-grade serous (LGSOC; 2.7%), CCOV (30%), endometrioid (EOV; 8.9%), and mucinous (MOV; 7.3%). Compared with Western cohorts, HGSOC was less frequent and CCOV more prevalent. Distinct mutational profiles were observed across subtypes:
conclusionThis large clinicogenomic study in an Asian population highlights unique mutational landscapes and survival associations, which may inform personalized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.